관리-도구

편집 파일: 1599417574.M753362P9421.server.saraya-global.com,S=16777,W=17279:2,

Envelope-to: info@worldwide.saraya.com
Delivery-date: Mon, 07 Sep 2020 02:39:34 +0800
Date: Sun, 6 Sep 2020 20:38:42 +0200
To: info@worldwide.saraya.com
From: PMC Acquisitions + Licensing <info@licensing4pharma.de>
Reply-to: PMC Acquisitions + Licensing <info@licensing4pharma.de>
Message-ID: <744c031d38ee4f8b09a595d39a4637e6@www.licensing4pharma.com>
MIME-Version: 1.0
Content-Type: multipart/alternative;
	boundary="b1_744c031d38ee4f8b09a595d39a4637e6"
Subject: ***SPAM*** Divestments / Pharma

--b1_744c031d38ee4f8b09a595d39a4637e6
Content-Type: text/plain; charset = "iso-8859-1"
Content-Transfer-Encoding: 8bit

To view the message, please use an HTML compatible email viewer!

--b1_744c031d38ee4f8b09a595d39a4637e6
Content-Type: text/html; charset = "iso-8859-1"
Content-Transfer-Encoding: 8bit

Please forward to: Managing Director, CEO, Head of Business Development

Dear Madam, Dear Sir,&nbsp;

This is to inform you that we may offer to you the following pharmaceutical businesses &amp; brands to purchase

I. Company Sales:

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			1. Pharmaceutical Marketing Company - Niche OTC Brands
			</td>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Type of Business:
			</td>
			<td>&nbsp;Lean Marketing and Sales Company</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>Niche OTC Brands</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Employees:
			</td>
			<td>ca. 25</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>
			Germany, Austria, Switzerland

expansion in other EU-countries planned
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>share deal</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>&gt; 50 m Euro (strong growing)</td>
		</tr>
	</tbody>
</table>

&nbsp;

II. Brand Sales:

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2" style="white-space:nowrap">
			1. Niche-Rx-Brand&nbsp;in Internal Medicine / Emergency Treatment
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>
			&nbsp;Emergency treatment&nbsp;
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Product:
			</td>
			<td>
			Famous Niche Rx Brand, and Phase-III-Project for successor product
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>global</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>
			ca. 40 m EUR (growing)

Sales-Potential of the Phase-III-Project in the higher 3-digit million EUR range
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2" style="white-space:nowrap">
			2. Bundle of Rx-Brands / Inflammatory Diseases
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>
			&nbsp;Acute and chronic Inflammatory Diseases
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Product:
			</td>
			<td>Bundle of 7 famous Brands</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>mainly Europe (ca. 78% of sales)</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>
			ca. 40 m EUR
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

(registrations for 10 further countries available)
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment, including commercial infrastructure&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>ca. 4 m EUR (growing)</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			4. Bundle of RX-Brands to treat Disorders in Urology
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>Male&#39; s Health</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>RX-Brand, patent-protected</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>Europe (major sales in EU) 
			MA&#39;s for other countries available</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>&gt; 6 m EUR</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			5. OTC-Brands for treatment and prevention of Metabolic DIsorders
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>Internal Medicine</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>OTC-Brands</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>Germany, Austria</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>&gt; 16 m EUR</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			6. Bundle of 2 prescription-only CV-Brands&nbsp;&nbsp;
			</td>
		</tr>
		<tr>
			<td colspan="2">
			&nbsp;
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>Cardiovascular System</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>Rx-Brands</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>Hungary</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>~ 1.2 m EUR</td>
		</tr>
	</tbody>
</table>

among many others...

If you are currently&nbsp;seeking to acquire any businesses in Pharma &amp; Healthcare we may assist you to find suitable targets.

We will provide you on the basis of an existing business relationship immediatly with confidential information on the businesses of interest. If no business relationship exists up to now we would have to conclude first a standard commission agreement (buy-side mandate) allowing us to exchange further details.

If you desire to divest any businesses or non-core assets we may support you efficetively to identify suitable buyers and to manage the entire sales process until successful closure of the transaction. We built up a proven network of business relations to strategic and financial investors worldwide over the past 20 years enabling us to assist you accordingly.

Looking&nbsp;forward to hearing from you.&nbsp;

Mit bestem Dank und freundlichen Gr&uuml;&szlig;en aus Zug 
Many thanks and best regards from Zug in Switzerland&nbsp;

Marc Raber

Dr. M. Raber 
Managing Director/Gesch&auml;ftsf&uuml;hrer

NB:&nbsp;Information on Corporate Sales, Brand Sales, Partnering Opportunities and Registrations &amp; Files&nbsp;you may find on our website.&nbsp;Register there for free (if not already done), enter the M&amp;A Database and search&nbsp;it for&nbsp;business opportunities. Detailed information on interesting businesses you may request directly through the database.

PMC Pharma Management Consultants GmbH 
Alisbachweg 22c 
CH-6315 Oberaegeri (Zug) 
Switzerland

<table border="0" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>Phone:</td>
			<td>+41 (0) 41 720 20 22&nbsp;</td>
		</tr>
		<tr>
			<td>Fax:</td>
			<td>+41 (0) 41 720 20 23&nbsp;</td>
		</tr>
		<tr>
			<td>Mobile:</td>
			<td>+41 (0) 79 358 21 86</td>
		</tr>
		<tr>
			<td>Web:</td>
			<td><a href="*link_url*">www.licensing4pharma.com</a></td>
		</tr>
		<tr>
			<td>Email:</td>
			<td><a href="mailto:info@licensing4pharma.com">info@licensing4pharma.com</a></td>
		</tr>
	</tbody>
</table>

&nbsp;

This e-mail was sent to info@worldwide.saraya.com !<img id='_x0000_i1024' src='http://www.licensing4pharma.com/images/button_pen.gif' style='height:22px; width:23px' />&nbsp;<a href='https://www.licensing4pharma.com/pmcfiles/app/index_confirmed.php?tk=cUZOaXoyWEdwUGdlek8yaldWYVdkenYzNXVyd1drem9xaEVaYWNIU1pRdz0='>Review and update</a> your settings (to provide you with suitable M&A opportunities you are looking for) or <a href='https://www.licensing4pharma.com/unsubscribe.php?url=YmM5NzE='> unsubscribe instantly</a>
</body></html>

--b1_744c031d38ee4f8b09a595d39a4637e6--